Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nouri Neamati

Showing results (1-10 of 239) with videos related to

Pageof 24
Sort By:
Expert Opinion on Investigational Drugs|January 31, 2003
Dipyrimidine-based inhibitors of HIV-1 integraseNouri Neamati
Journal of Medicinal Chemistry|February 9, 2022
Advances Toward COVID-19 Therapies Special IssueNouri Neamati
Core Evidence|August 10, 2010
Raltegravir: The evidence of its therapeutic value in HIV-1 infectionKavya Ramkumar, Nouri Neamati
Bioorganic & Medicinal Chemistry Letters|August 2, 2006
Inhibition of HIV-1 integrase activity by synthetic peptides derived from the HIV-1 HXB2 Pol region of the viral genomeZahrah Zawahir, Nouri Neamati
Expert Opinion on Therapeutic Targets|October 9, 2013
gp130: a promising drug target for cancer therapyShili Xu, Nouri Neamati
Current Pharmaceutical Design|July 23, 2003
Small-molecule HIV-1 integrase inhibitors: the 2001-2002 updateRaveendra Dayam, Nouri Neamati
Bioorganic & Medicinal Chemistry|November 24, 2004
Active site binding modes of the beta-diketoacids: a multi-active site approach in HIV-1 integrase inhibitor designRaveendra Dayam, Nouri Neamati
ACS Pharmacology & Translational Science|January 19, 2023
Inhibition of Protein Disulfide Isomerase (PDIA1) Leads to Proteasome-Mediated Degradation of Ubiquitin-like PHD and RING Finger Domain-Containing Protein 1 (UHRF1) and Increased Sensitivity of Glioblastoma Cells to Topoisomerase II InhibitorsRima Mouawad, Nouri Neamati
Molecular Pharmaceutics|June 5, 2014
Pyrimidine-based compounds modulate CXCR2-mediated signaling and receptor turnoverHelen Ha, Nouri Neamati
Current Topics in Medicinal Chemistry|March 4, 2015
Membrane permeable lipophilic cations as mitochondrial directing groupsJoseph T Madak, Nouri Neamati
Pageof 24

Showing results (1-10 of 239) with videos related to

Sort By:
Pageof 24
Expert Opinion on Investigational Drugs|January 31, 2003
Dipyrimidine-based inhibitors of HIV-1 integraseNouri Neamati
Journal of Medicinal Chemistry|February 9, 2022
Advances Toward COVID-19 Therapies Special IssueNouri Neamati
Core Evidence|August 10, 2010
Raltegravir: The evidence of its therapeutic value in HIV-1 infectionKavya Ramkumar, Nouri Neamati
Bioorganic & Medicinal Chemistry Letters|August 2, 2006
Inhibition of HIV-1 integrase activity by synthetic peptides derived from the HIV-1 HXB2 Pol region of the viral genomeZahrah Zawahir, Nouri Neamati
Expert Opinion on Therapeutic Targets|October 9, 2013
gp130: a promising drug target for cancer therapyShili Xu, Nouri Neamati
Current Pharmaceutical Design|July 23, 2003
Small-molecule HIV-1 integrase inhibitors: the 2001-2002 updateRaveendra Dayam, Nouri Neamati
Bioorganic & Medicinal Chemistry|November 24, 2004
Active site binding modes of the beta-diketoacids: a multi-active site approach in HIV-1 integrase inhibitor designRaveendra Dayam, Nouri Neamati
ACS Pharmacology & Translational Science|January 19, 2023
Inhibition of Protein Disulfide Isomerase (PDIA1) Leads to Proteasome-Mediated Degradation of Ubiquitin-like PHD and RING Finger Domain-Containing Protein 1 (UHRF1) and Increased Sensitivity of Glioblastoma Cells to Topoisomerase II InhibitorsRima Mouawad, Nouri Neamati
Molecular Pharmaceutics|June 5, 2014
Pyrimidine-based compounds modulate CXCR2-mediated signaling and receptor turnoverHelen Ha, Nouri Neamati
Current Topics in Medicinal Chemistry|March 4, 2015
Membrane permeable lipophilic cations as mitochondrial directing groupsJoseph T Madak, Nouri Neamati
Pageof 24